reports
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. “We are delighted to welcome Svetlana to Prime Medicine,” said Allan Re...
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s No...
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile Access the Moleculin CEO Corner HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. A...
Immuneering to Present at the 25th Annual Needham Virtual Healthcare C...
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering’s website at . About Immunee...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ORIC INC.
U ORIC PHARMACEUTICALS
BUR UNITY SOFTWARE
STX BURFORD CAPITAL
UWMC SEAGATE TECHNOLOGY HLDGS PLC
GFS UWM HLDGS CORP
MLTX GLOBALFOUNDRIES INC
EWTX MOONLAKE IMMUNOTHERAPEUTICS
BCAX EDGEWISE THERAPEUTICS INC
BICARA THERAPEUTICS INC.
- Michael Piccolo
Daily Recap: U, TWO/UWMC, NVS, BF.B/RI, BCE/MSI, JHG/VCTR, WBD/PSKY, H...
Two Harbors Investment Corp. (TWO - $11.40) and UWM Holdings Corp. (UWMC - $3.53)Announces New Merger Agreement; Offer Value $10.80/share; Terminates Existing Merger Agreement. TWO announced today a definitive merger agreement with CrossCountry Mortgage, LLC ("CCM"), under which CCM will acquire al
- Jonathan Moreland
WAT WATERS CORPORATION
VNO VORNADO REALTY TRUST
TGL. TECNOGLASS INC.
SCM STELLUS CAPITAL INVESTMENT CORP
ROCK GIBRALTAR INDUSTRIES INC.
POOL POOL CORPORATION
OSUR ORASURE TECHNOLOGIES INC.
NSP INSPERITY INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NFBK NORTHFIELD BANCORP INC.
MTN VAIL RESORTS INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
BBSI BARRETT BUSINESS SERVICES INC.
WD WALKER & DUNLOP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
BWFG BANKWELL FINANCIAL GROUP
SVRA SAVARA
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ULBI ULTRALIFE
SONO SONOS
EML THE EASTERN COMPANY
STIM STIMSONITE CORP
BLDR BUILDERS FIRSTSOURCE
AEYE INC.
PHR AUDIOEYE INC
AHCO PHREESIA
AVO ADAPTHEALTH
AMR MISSION PRODUCE
TRIN ALPHA METALLURGICAL RESOURCES INC
AIRS TRINITY CAPITAL INC
EXFY AIRSCULPT TECHNOLOGIES INC
SBSW EXPENSIFY INC
VANI SIBANYE-STILLWATER LTD
GRNT VIVANI MEDICAL INC
NBBK GRANITE RIDGE RESOURCES INC
SDHC NB BANCORP INC.
MXF SMITH DOUGLAS HOMES CORP
SNES THE MEXICO FUND
GF INC.
AFCG SENESTECH INC.
SI THE NEW GERMANY FUND
SENS INC.
AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
SENSEONICS HOLDINGS INC.
- Jonathan Moreland
ALDX ALDEYRA THERAPEUTICS
BBSI BARRETT BUSINESS SERVICES INC.
WD WALKER & DUNLOP INC.
PLBC PLUMAS BANCORP
SVRA SAVARA
EML THE EASTERN COMPANY
STIM STIMSONITE CORP
AMR ALPHA METALLURGICAL RESOURCES INC
ZIP ZIPRECRUITER
AIRS INC.
JOBY AIRSCULPT TECHNOLOGIES INC
INDI JOBY AVIATION INC
NBBK INDIE SEMICONDUCTOR INC
MXF NB BANCORP INC.
GF THE MEXICO FUND
EKSO INC.
THE NEW GERMANY FUND
INC.
EKSO BIONICS HOLDINGS INC.
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from...
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (...
Moleculin to Present at 38th Annual ROTH Conference
Moleculin to Present at 38th Annual ROTH Conference – Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in a fireside chat at the being held March 22-24, 2026 in Dana Point, CA. Details of the fireside chat presentation are as follows: Date and Time: Tuesday, March 24, 2026 at 12:00-12:25 PM PTLocation: BROWN - HEALTHCARE - VIRTUAL (SUITE 1051)Presenters...
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study Access the Moleculin CEO Corner HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company’s corporate developments, clinical progress and strategic initiatives. As part of the segment, Mr. Klemp discussed progress on the Company’s p...
- Jonathan Moreland
CSGP COSTAR GROUP INC
XRAY DENTSPLY SIRONA INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
NWBI NORTHWEST BANCSHARES INC.
MYGN MYRIAD GENETICS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
WHF WHITEFIELD
ORN ORION GROUP HOLDINGS
THO THOR INDUSTRIES INC.
TTEC TELETECH HOLDINGS
HOG INC.
GO HARLEY-DAVIDSON INC.
ALT GROCERY OUTLET HOLDING
TSLX ALTIMMUNE INC
VERX SIXTH STREET SPECIALTY LENDING
ADV INC.
TKNO VERTEX
AIRS INC.
QSI ADVANTAGE SOLUTIONS INC (A)
FRST ALPHA TEKNOVA
TCBX INC.
EBC AIRSCULPT TECHNOLOGIES INC
NBBK QUANTUM-SI INC
MXF PRIMIS FINANCIAL CORP
LYEL THIRD COAST BANCSHARES INC
EASTERN BANKSHARES INC
NB BANCORP INC.
THE MEXICO FUND
INC.
LYELL IMMUNOPHARMA INC.
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Result...
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 - - On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 - - Dosing in Phase 2 trial of at...
- Wedbush Research
SHOP SHOPIFY INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
STAA STAAR SURGICAL CO.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BBY BEST BUY CO. INC.
AXTI AXT INC.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
ANAB ANAPTYSBIO INC.
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
PASG INC.
BEAM PASSAGE BIO
DASH BEAM THERAPEUTICS
ABNB DOORDASH
PLTR AIRBNB INC. CLASS A
IMNM PALANTIR TECHNOLOGIES
SANA IMMUNOME
XMTR SANA BIOTECHNOLOGY
STX XOMETRY
TTD INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX THE TRADE DESK
PRME INC.
APGE GLOBALFOUNDRIES INC
CART MOONLAKE IMMUNOTHERAPEUTICS
IMA PRIME MEDICINE INC
VOYG APOGEE THERAPEUTICS INC
MAPLEBEAR INC.
IMAGENEBIO INC.
VOYAGER TECHNOLOGIES INC
Prime Medicine Reports Full Year 2025 Financial Results and Provides B...
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates -- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company commi...
- David Nierengarten
- Dennis Pak
- Martin Fan
Immuneering to Present at the Leerink Global Healthcare Conference
Immuneering to Present at the Leerink Global Healthcare Conference NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 9, 2026, f...
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: TD Cowen 46th Annual Health Care Conference: Fireside chat on Wednesday, March 4, 2026, at 1:10 p.m. ET in Boston, MA.2026 Jefferies Biotech on the Beach Summit: Company management will host 1x1 meetings on Tuesday, March 10, 2026, in Miam...
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Procee...
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant...
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life ...
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform, and ...
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=3...
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MB...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.